Iomai Corporation has announced positive interim results from its immunostimulant adjuvant patch phase 1/2 trial. The patch was used with the injected H5N1 influenza vaccine. A single 45-microgram dose of an H5N1 influenza vaccine with a single 50-microgram Iomai patch produced a sufficient protective response in 73% of tested patients. The figure showed substantial improvement over those who were administered the H5N1 influenza vaccine alone.